A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

计划入组 450 人 · 首次发布于 2025 年 4 月 6 日

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

计划入组 148 人 · 首次发布于 2025 年 1 月 8 日

Extension Program for Bay 43-9006

计划入组 9 人 · 首次发布于 2008 年 4 月 14 日

BAY-1165747

BAY-1161116

BAY-946

BAY PATH UNIVERSITY

United States

Sutter Bay Hospitals

United States

Kips Bay Medical, Inc.

United States

Bayer Secures Global License for Novel PRMT5 Inhibitor Targeting MTAP-Deleted Tumors

BAY 2927088 Demonstrates Promising Activity in HER2-Mutant NSCLC

MaineHealth Expands Cardiac Rehabilitation Programs at Pen Bay and Waldo Hospitals